Skip to main content
Top
Published in: Infectious Diseases and Therapy 3/2020

Open Access 01-09-2020 | Antacid | Case Report

HIV-1 Virologic Rebound Due to Coadministration of Divalent Cations and Bictegravir

Authors: Alex E. Rock, Patricia L. DeMarais, Pamala T. Vergara-Rodriguez, Blake E. Max

Published in: Infectious Diseases and Therapy | Issue 3/2020

Login to get access

Abstract

A potential drug-drug interaction exists between divalent and trivalent cations (Ca2+, Fe3+, Mg2+, Al3+, Zn2+) and HIV-1 integrase strand transfer inhibitors (INSTIs). There are limited case reports describing the clinical significance of this potential interaction and none to our knowledge identifying zinc co-administration with INSTIs. In this report we present a patient taking bictegravir/emtricitabine/tenofovir alafenamide who became viremic after ingesting zinc and calcium supplements and later was able to obtain virologic re-suppression after discontinuing supplements. This case represents a potential significant drug interaction between a commonly prescribed antiretroviral drug class and readily available over-the-counter divalent cation products.
Literature
2.
go back to reference Hajimahdi Z, Zarghi A. Progress in HIV-1 integrase inhibitors: a review of their chemical structure diversity. Iran J Pharm Res. 2016;15(4):595–628.PubMedPubMedCentral Hajimahdi Z, Zarghi A. Progress in HIV-1 integrase inhibitors: a review of their chemical structure diversity. Iran J Pharm Res. 2016;15(4):595–628.PubMedPubMedCentral
3.
go back to reference Song I, Borland J, Arya N, Wynne B, Piscitelli S. Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects. J Clin Pharmacol. 2015;55(5):490–6.CrossRefPubMed Song I, Borland J, Arya N, Wynne B, Piscitelli S. Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects. J Clin Pharmacol. 2015;55(5):490–6.CrossRefPubMed
4.
go back to reference Krishna R, East L, Larson P, et al. Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravir. J Pharm Pharmacol. 2016;68(11):1359–65.CrossRefPubMed Krishna R, East L, Larson P, et al. Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravir. J Pharm Pharmacol. 2016;68(11):1359–65.CrossRefPubMed
5.
go back to reference Forst TM, Dinges WL. Coadministration of divalent cation mineral supplements causes CART virologic failure and hiv mutagenesis: a Case Study. Clin J HIV AIDS. 2018;2(1):26–7. Forst TM, Dinges WL. Coadministration of divalent cation mineral supplements causes CART virologic failure and hiv mutagenesis: a Case Study. Clin J HIV AIDS. 2018;2(1):26–7.
6.
go back to reference Tivicay (dolutegravir) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; August 2013. Tivicay (dolutegravir) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; August 2013.
7.
go back to reference Triumeq (dolutegravir/abacavir/lamivudine) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; August 2014. Triumeq (dolutegravir/abacavir/lamivudine) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; August 2014.
8.
go back to reference Dovato (dolutegravir/lamivudine) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; April 2019. Dovato (dolutegravir/lamivudine) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; April 2019.
9.
go back to reference Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir desoproxil fumarate) [package insert]. Foster City, CA: Gilead Sciences, Inc.; August 2017. Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir desoproxil fumarate) [package insert]. Foster City, CA: Gilead Sciences, Inc.; August 2017.
10.
go back to reference Genvoya (elvitegravir. cobicistat, emtricitabine, tenofovir alafenamide) [package insert]. Foster City, CA: Gilead Sciences, Inc.; December 2016. Genvoya (elvitegravir. cobicistat, emtricitabine, tenofovir alafenamide) [package insert]. Foster City, CA: Gilead Sciences, Inc.; December 2016.
11.
go back to reference Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) [package insert]. Foster City, CA: Gilead Sciences, Inc; February 2018. Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) [package insert]. Foster City, CA: Gilead Sciences, Inc; February 2018.
12.
go back to reference Isentress (raltegravir) [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; August 2013. Isentress (raltegravir) [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; August 2013.
14.
go back to reference Lodha R, Shah N, Mohari N, et al. Immunologic effect of zinc supplementation in HIV-infected children receiving highly active antiretroviral therapy: a randomized, double-blind, placebo-controlled trial. J Acquir Immune Defic Syndr. 2014;66(4):386–92.CrossRefPubMed Lodha R, Shah N, Mohari N, et al. Immunologic effect of zinc supplementation in HIV-infected children receiving highly active antiretroviral therapy: a randomized, double-blind, placebo-controlled trial. J Acquir Immune Defic Syndr. 2014;66(4):386–92.CrossRefPubMed
15.
go back to reference Motswagole BS, Mongwaketse TC, Mokotedi M, et al. The efficacy of micronutrient-fortified sorghum meal in improving the immune status of HIV-positive adults. Ann Nutr Metab. 2013;62(4):323–30.CrossRefPubMed Motswagole BS, Mongwaketse TC, Mokotedi M, et al. The efficacy of micronutrient-fortified sorghum meal in improving the immune status of HIV-positive adults. Ann Nutr Metab. 2013;62(4):323–30.CrossRefPubMed
16.
go back to reference Ndeezi G, Tylleskar T, Ndugwa CM, Tumwine JK. Effect of multiple micronutrient supplementation on survival of HIV-infected children in Uganda: a randomized, controlled trial. J Int AIDS Soc. 2010;13:18.CrossRefPubMedPubMedCentral Ndeezi G, Tylleskar T, Ndugwa CM, Tumwine JK. Effect of multiple micronutrient supplementation on survival of HIV-infected children in Uganda: a randomized, controlled trial. J Int AIDS Soc. 2010;13:18.CrossRefPubMedPubMedCentral
17.
go back to reference Sundaram M, Saghayam S, Priya B, et al. Changes in antioxidant profile among HIV-infected individuals on generic highly active antiretroviral therapy in southern India. Int J Infect Dis. 2008;12(6):e61–6.CrossRefPubMed Sundaram M, Saghayam S, Priya B, et al. Changes in antioxidant profile among HIV-infected individuals on generic highly active antiretroviral therapy in southern India. Int J Infect Dis. 2008;12(6):e61–6.CrossRefPubMed
18.
go back to reference Green JA, Lewin SR, Wightman F, Lee M, Ravindran TS, Paton NI. A randomised controlled trial of oral zinc on the immune response to tuberculosis in HIV-infected patients. Int J Tuberc Lung Dis. 2005;9(12):1378–84.PubMed Green JA, Lewin SR, Wightman F, Lee M, Ravindran TS, Paton NI. A randomised controlled trial of oral zinc on the immune response to tuberculosis in HIV-infected patients. Int J Tuberc Lung Dis. 2005;9(12):1378–84.PubMed
19.
go back to reference Villamor E, Aboud S, Koulinska IN, et al. Zinc supplementation to HIV-1-infected pregnant women: effects on maternal anthropometry, viral load, and early mother-to-child transmission. Eur J Clin Nutr. 2006;60(7):862–9.CrossRefPubMed Villamor E, Aboud S, Koulinska IN, et al. Zinc supplementation to HIV-1-infected pregnant women: effects on maternal anthropometry, viral load, and early mother-to-child transmission. Eur J Clin Nutr. 2006;60(7):862–9.CrossRefPubMed
20.
go back to reference Bobat R, Coovadia H, Stephen C, et al. Safety and efficacy of zinc supplementation for children with HIV-1 infection in South Africa: a randomised double-blind placebo-controlled trial. Lancet. 2005;366(9500):1862–7.CrossRefPubMed Bobat R, Coovadia H, Stephen C, et al. Safety and efficacy of zinc supplementation for children with HIV-1 infection in South Africa: a randomised double-blind placebo-controlled trial. Lancet. 2005;366(9500):1862–7.CrossRefPubMed
21.
go back to reference Fawzi WW, Villamor E, Msamanga GI, et al. Trial of zinc supplements in relation to pregnancy outcomes, hematologic indicators, and T cell counts among HIV-1-infected women in Tanzania. Am J Clin Nutr. 2005;81(1):161–7.CrossRefPubMed Fawzi WW, Villamor E, Msamanga GI, et al. Trial of zinc supplements in relation to pregnancy outcomes, hematologic indicators, and T cell counts among HIV-1-infected women in Tanzania. Am J Clin Nutr. 2005;81(1):161–7.CrossRefPubMed
22.
go back to reference Reich EN, Church JA. Oral zinc supplementation in the treatment of HIV-infected children. Pediatr AIDS HIV Infect. 1994;5(6):357–60.PubMed Reich EN, Church JA. Oral zinc supplementation in the treatment of HIV-infected children. Pediatr AIDS HIV Infect. 1994;5(6):357–60.PubMed
23.
go back to reference Baum MK, Lai S, Sales S, Page JB, Campa A. Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV-infected adults. Clin Infect Dis. 2010;50(12):1653–60.CrossRefPubMed Baum MK, Lai S, Sales S, Page JB, Campa A. Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV-infected adults. Clin Infect Dis. 2010;50(12):1653–60.CrossRefPubMed
24.
go back to reference Zhao F, Wang Z, Li WJ. Impact of micronutrients on immunocyte and microelements status among people living with HIV. Zhonghua Liu Xing Bing Xue Za Zhi. 2009;30(5):452–4.PubMed Zhao F, Wang Z, Li WJ. Impact of micronutrients on immunocyte and microelements status among people living with HIV. Zhonghua Liu Xing Bing Xue Za Zhi. 2009;30(5):452–4.PubMed
25.
go back to reference Asdamongkol N, Phanachet P, Sungkanuparph S. Low plasma zinc levels and immunological responses to zinc supplementation in HIV-infected patients with immunological discordance after antiretroviral therapy. Jpn J Infect Dis. 2013;66(6):469–74.CrossRefPubMed Asdamongkol N, Phanachet P, Sungkanuparph S. Low plasma zinc levels and immunological responses to zinc supplementation in HIV-infected patients with immunological discordance after antiretroviral therapy. Jpn J Infect Dis. 2013;66(6):469–74.CrossRefPubMed
26.
go back to reference Moyle G, Else L, Jackson A, et al. Coadministration of atazanavir-ritonavir and zinc sulfate: impact on hyperbilirubinemia and pharmacokinetics. Antimicrob Agents Chemother. 2013;57(8):3640–4.CrossRefPubMedPubMedCentral Moyle G, Else L, Jackson A, et al. Coadministration of atazanavir-ritonavir and zinc sulfate: impact on hyperbilirubinemia and pharmacokinetics. Antimicrob Agents Chemother. 2013;57(8):3640–4.CrossRefPubMedPubMedCentral
27.
go back to reference Bunupuradah T, Ubolyam S, Hansudewechakul R, et al. Correlation of selenium and zinc levels to antiretroviral treatment outcomes in Thai HIV-infected children without severe HIV symptoms. Eur J Clin Nutr. 2012;66(8):900–5.CrossRefPubMedPubMedCentral Bunupuradah T, Ubolyam S, Hansudewechakul R, et al. Correlation of selenium and zinc levels to antiretroviral treatment outcomes in Thai HIV-infected children without severe HIV symptoms. Eur J Clin Nutr. 2012;66(8):900–5.CrossRefPubMedPubMedCentral
28.
go back to reference Gnatienko N, Freiberg MS, Blokhina E, et al. Design of a randomized controlled trial of zinc supplementation to improve markers of mortality and HIV disease progression in HIV-positive drinkers in St. Petersburg, Russia. HIV Clin Trials. 2018;19(3):101–11.CrossRefPubMedPubMedCentral Gnatienko N, Freiberg MS, Blokhina E, et al. Design of a randomized controlled trial of zinc supplementation to improve markers of mortality and HIV disease progression in HIV-positive drinkers in St. Petersburg, Russia. HIV Clin Trials. 2018;19(3):101–11.CrossRefPubMedPubMedCentral
29.
go back to reference Jung S, Kim MK, Choi BY. The relationship between zinc status and inflammatory marker levels in rural Korean adults aged 40 and older. PLoS One. 2015;10(6):e0130016.CrossRefPubMedPubMedCentral Jung S, Kim MK, Choi BY. The relationship between zinc status and inflammatory marker levels in rural Korean adults aged 40 and older. PLoS One. 2015;10(6):e0130016.CrossRefPubMedPubMedCentral
Metadata
Title
HIV-1 Virologic Rebound Due to Coadministration of Divalent Cations and Bictegravir
Authors
Alex E. Rock
Patricia L. DeMarais
Pamala T. Vergara-Rodriguez
Blake E. Max
Publication date
01-09-2020
Publisher
Springer Healthcare
Published in
Infectious Diseases and Therapy / Issue 3/2020
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI
https://doi.org/10.1007/s40121-020-00307-4

Other articles of this Issue 3/2020

Infectious Diseases and Therapy 3/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.